Showing results (311-320 of 327) with videos related to
Sort By:
Pageof 33
Cancers|May 14, 2022
Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled TrialAnna Ozaki, Takaomi Kessoku, Kosuke Tanaka, et al.Contemporary Clinical Trials Communications|July 11, 2022
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipationAtsushi Yamamoto, Takaomi Kessoku, Kosuke Tanaka, et al.Human Molecular Genetics|August 4, 2021
De novo ARF3 variants cause neurodevelopmental disorder with brain abnormalityMasamune Sakamoto, Kazunori Sasaki, Atsushi Sugie, et al.Clinical & Experimental Metastasis|March 9, 2018
Time-dependent change in relapse sites of renal cell carcinoma after curative surgeryGo Noguchi, Noboru Nakaigawa, Masataka Taguri, et al.Cancer Science|August 25, 2025
Cystathionine as a Potential Urinary Marker for Diagnosing and Assessing Pretreatment Risk in NeuroblastomaHizuru Amano, Yoshiharu Hayashi, Kazuharu Harada, et al.Annals of Neurology|November 10, 2018
Biallelic COLGALT1 variants are associated with cerebral small vessel diseaseSatoko Miyatake, Sacha Schneeberger, Norihisa Koyama, et al.Cancer Science|February 27, 2024
Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinationsHizuru Amano, Hiroo Uchida, Kazuharu Harada, et al.Journal of Hepato-Biliary-Pancreatic Sciences|January 7, 2026
Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression ModelDenys Tsybulskyi, Daisuke Hashimoto, Kimitaka Tanaka, et al.BMJ Open|May 31, 2022
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipationKosuke Tanaka, Takaomi Kessoku, Atsushi Yamamoto, et al.Med (New York, N.Y.)|July 28, 2021
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosisNaoto Fujiwara, Masahiro Kobayashi, Austin J Fobar, et al.Pageof 33